Cepheid PT Raised to $57.00 (CPHD)
Research analysts at Raymond James raised their price objective on shares of Cepheid (NASDAQ:CPHD) from $50.00 to $57.00 in a report released on Friday, AnalystRatings.Net reports. Raymond James’ price target would indicate a potential upside of 7.83% from the company’s current price.
Cepheid (NASDAQ:CPHD) opened at 52.86 on Friday. Cepheid has a one year low of $30.95 and a one year high of $54.45. The stock’s 50-day moving average is $47.00 and its 200-day moving average is $40.85. The company’s market cap is $3.586 billion.
Cepheid (NASDAQ:CPHD) last released its earnings data on Friday, January 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million. On average, analysts predict that Cepheid will post $0.01 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of Cepheid from $43.00 to $54.00 in a research note to investors on Friday. Separately, analysts at UBS AG raised their price target on shares of Cepheid from $48.00 to $55.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at ISI Group raised their price target on shares of Cepheid from $38.00 to $39.00 in a research note to investors on Friday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. Cepheid currently has an average rating of “Hold” and an average target price of $48.25.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.